Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving the German biotech trying to find a silver lining in the drug’s potential ...
AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis (UC) after the PD-1 agonist flunked a phase 2 study. The San Diego-based biopharma assessed rosnilimab in the midstage study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback